Tumor Genomic Profiling with SureSelect Cancer Tumor-Specific Assays

With Agilent SureSelect Cancer Tumor-Specific assays, focused cancer NGS panels comprised of approximately 50 genes each, you can detect key classes of somatic alterations (SNVs, CNVs, indels, DNA translocations) from lung, colon, pancreas, kidney, and bladder tissue samples. For de novo gene fusion detection, the modular workflow allows the option to combine a SureSelect Cancer Tumor-Specific DNA assay with SureSelect Cancer CGP RNA assay (80 genes) in the same sequencing run. Obtain high-performance results optimized with error-correcting molecular barcodes, convenient enzymatic fragmentation and minimal sample input. Workflows are configurable with options to incorporate sample QC, automation, and data analysis solutions.

>> Download Data Sheet as a PDF

Find out more on Agilent's website here

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe